Study in Healthy Adults Evaluating PF-07202954

• Status: Recruiting
• Trial end date: 2022-03-08
• Target enrollment: 0
• Participant gender: All

Summary

The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:- healthy subjects (all 3 Parts)

• evidence of steatosis on FibroScan (Part 2 only)

• BMI 17.5 to 30.5 kg/m2 (Part 1, Part 3)

• BMI 17.5 to 35.4 kg/m2 (Part 2) Exclusion Criteria:- evidence of clinically significant disease

• subjects on chronic medications

• clinically significant, abnormal laboratory results, vital signs, or cardiac conduction abnormalities

• contraindication to MRI (Part 2, only)